

Elena LÃ³pez-Knowles

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2822625/publications.pdf>

Version: 2024-02-01

15
papers

1,477
citations

759055

12
h-index

996849

15
g-index

15
all docs

15
docs citations

15
times ranked

3241
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of <i>ESR1</i> mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. <i>Science Translational Medicine</i> , 2015, 7, 313ra182.	5.8	460
2	Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. <i>Lancet Oncology</i> , The, 2013, 14, 1067-1076.	5.1	332
3	Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score. <i>Journal of Clinical Oncology</i> , 2015, 33, 916-922.	0.8	189
4	Breast cancer risk variants at 6q25 display different phenotype associations and regulate <i>ESR1</i> , <i>RMND1</i> and <i>CCDC170</i> . <i>Nature Genetics</i> , 2016, 48, 374-386.	9.4	125
5	Tumor <i>PIK3CA</i> Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. <i>Journal of Clinical Oncology</i> , 2018, 36, 981-990.	0.8	95
6	Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. <i>Clinical Cancer Research</i> , 2020, 26, 608-622.	3.2	71
7	Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 743-750.	0.8	58
8	Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2763-2770.	3.2	36
9	Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation. <i>Nature Communications</i> , 2016, 7, 13294.	5.8	34
10	Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas. <i>Breast Cancer Research</i> , 2016, 18, 39.	2.2	24
11	Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients. <i>Breast Cancer Research</i> , 2020, 22, 2.	2.2	15
12	Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of <i>ESR1</i> mutations. <i>British Journal of Cancer</i> , 2019, 120, 247-255.	2.9	13
13	Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky005.	1.4	11
14	Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 35.	2.2	8
15	Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor-positive Breast Cancers. <i>Clinical Cancer Research</i> , 2022, 28, 1217-1228.	3.2	6